Document detail

WHO issued updated guidelines on the management of multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C). MIS-C is a rare but serious condition where children with COVID-19 develop inflammation affecting different organs of the body. Children with this condition need specialized care, and may need to be admitted to intensive care. Although MIS-C is a serious condition, with the right medical care, children with this condition recover. WHO’s updated guidelines recommend the use of corticosteroids in hospitalized children (aged 0-18 years) with this condition, in addition to supportive treatment and care. This recommendation comes following the availability of three observational studies, pooling data from 885 patients in total. 3rd edition 23rd November 2021

clinical care,  Treatment,  guideline,  COVID-19,  pediatric,  multisystem inflammatory syndrome,